Teladoc’s mental health arm BetterHelp has quietly expanded the use of AInews2026-01-20T13:00:44+00:00January 20th, 2026|Endpoints News|
2025 ended on high note with a buoyant Q4 for M&A, PIPEs and follow-onsnews2026-01-20T13:00:25+00:00January 20th, 2026|Endpoints News|
Pfizer to depart GSK’s ViiV as Shionogi doubles its stakenews2026-01-20T12:02:06+00:00January 20th, 2026|Endpoints News|
Corvus’ new Phase 1 atopic dermatitis data meet high expectationsnews2026-01-20T12:00:19+00:00January 20th, 2026|Endpoints News|
J&J, Isomorphic sign research deal for AI-made moleculesnews2026-01-20T12:00:09+00:00January 20th, 2026|Endpoints News|
GSK makes $2.2B deal for RAPT and its food allergy candidatenews2026-01-20T10:34:11+00:00January 20th, 2026|Endpoints News|
Exciva raises $59M Series B to fund Phase 2 test of Alzheimer’s agitation drugnews2026-01-20T06:30:30+00:00January 20th, 2026|Endpoints News|
JPM recap; Mirador raises $250M; Genentech’s PBM shift; and more news2026-01-17T11:00:32+00:00January 17th, 2026|Endpoints News|
Agomab and SpyGlass file for IPOs as investor enthusiasm builds after JPMnews2026-01-16T22:05:40+00:00January 16th, 2026|Endpoints News|
AbbVie, Genmab say Epkinly didn’t prolong overall survival in lymphoma studynews2026-01-16T21:01:22+00:00January 16th, 2026|Endpoints News|
